RxDoctor Payments Data

Brian Cady, MD

Internal Medicine · Moline, ILNPI 1083619134

Payments from drug & device makers

$5,987in general payments, 2019–2025

Across 415 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$537
  • Pfizer$510
  • Novo Nordisk$401
  • Boehringer Ingelheim$305
  • Amgen$296
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,973100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,987 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$223,338
Medicare patients
613
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban249$218,711
RybelsusSemaglutide119$182,517
JardianceEmpagliflozin122$175,700
JanuviaSitagliptin Phosphate114$137,947
OzempicSemaglutide85$109,487
MounjaroTirzepatide76$102,653
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$78,576
RexultiBrexpiprazole37$65,802
Soliqua 100-33Insulin Glargine/Lixisenatide64$63,314
Xultophy 100-3.6Insulin Degludec/Liraglutide38$61,876
GlyxambiEmpagliflozin/Linagliptin32$55,567
InvokanaCanagliflozin44$52,138
TradjentaLinagliptin41$49,894
Tresiba Flextouch U-200Insulin Degludec25$47,030
FarxigaDapagliflozin Propanediol41$46,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6$401$353,880242 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Stiolto Respimat$305$290,376212 claims
PfizerEliquis, Eucrisa$510$227,708261 claims
MerckJanuvia, Belsomra$154$159,474163 claims
Lilly USA, LLCMounjaro$199$102,65376 claims
Johnson & JohnsonInvokana, Xarelto$168$97,87193 claims
GSKTrelegy Ellipta$242$78,576111 claims
AstraZenecaFarxiga, Breztri Aerosphere$537$74,70464 claims
Otsuka America Pharmaceutical, Inc.Rexulti$116$65,80237 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$74$63,31464 claims
Astellas Pharma US IncMyrbetriq$63$43,97947 claims
AbbVieLinzess, Namzaric$1,176$42,96753 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →